Новости и обновления Avalyn

Avalyn Pharma outlines inhaled fibrosis push after IPO, with pivotal data ahead

Avalyn Pharma (NASDAQ:AVLN) executives outlined the company's inhaled pulmonary fibrosis strategy at...

Jun 05, 2026 • MarketBeat on MSN

Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves

Why Avalyn Pharma is on investors’ radar Avalyn Pharma (AVLN) has drawn attention after recent sha...

Jun 01, 2026 • Yahoo Finance

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PP...

Jun 03, 2026 • Yahoo Finance

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...

May 05, 2026 • Markets Insider

Avalyn to Participate in the Jefferies Global Healthcare Conference

Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...

Jun 01, 2026 • Yahoo Finance UK

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for ...

Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...

May 21, 2026 • Markets Insider

Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline

Avalyn Pharma Inc. (AVLN) has filed to raise capital for its treatment pipeline development, accordi...

Apr 10, 2026 • Seeking Alpha

Avalyn Pharma Inc AVLN

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...

Jun 05, 2026 • Morningstar

Avalyn Announces Pricing of Upsized Initial Public Offering

BOSTON, April 29, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc. (Nasdaq: AVLN) ("Avalyn”), a clinical...

Apr 29, 2026 • manilatimes

Avalyn: Q1 Earnings Snapshot

Avalyn Pharma Inc. (AVLN) on Wednesday reported a loss of $26.9 million in its first quarter....

Jun 03, 2026 • The Advocate

Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...

Jul 21, 2025 • manilatimes

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

BOSTON, April 27, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc., a clinical-stage biopharmaceutical com...

Apr 27, 2026 • Taiwan News

Avalyn Pharma Sets IPO at 16.7 Million Shares Priced at $16-$18 Each

Avalyn Pharma on Wednesday plans to sell nearly 16.7 million shares at between $16 and $18 apiece in...

Apr 29, 2026 • MarketWatch

Keyword: avalyn hunter

Kingmambo excelled at a mile on the track but his offspring have shown a mix of speed and stamina. H...

Jul 13, 2010 • The Blood-Horse

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fun...

Apr 29, 2026 • FierceBiotech

Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials

The lung disease idiopathic pulmonary fibrosis (IPF) has few available treatments, and that medical ...

Oct 01, 2023 • MedCity News

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceu...

Apr 30, 2024 • Yahoo Finance

Avalyn Pharma Surges 44% After $300 Million Upsized IPO

Avalyn opened at $26, above its $18 IPO price, giving the rare lung disease biotech a market value o...

Apr 30, 2026 • Yahoo Finance

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...

May 01, 2026 • Markets Insider

Avalyn Pharma Inc

View Avalyn Pharma Inc AVLN stock quote prices, financial information, real-time forecasts, and comp...

Apr 25, 2026 • CNN

Avalyn Pharma Upsized IPO Priced at Top of Expectations

Shares of Avalyn Pharma are set to make their trading debut Thursday after the clinical-stage biopha...

Apr 30, 2026 • MarketWatch

Avalyn seeks $300m from its IPO

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscale...

Apr 29, 2026 • pharmaphorum

Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib

CAMBRIDGE, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...

Aug 11, 2024 • Yahoo Finance

Avalyn to Participate in Upcoming Investor Conference in April

CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmac...

Oct 03, 2025 • The National Law Review

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 ...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceu...

May 12, 2024 • Yahoo Finance

Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials

The few drugs available for lung disorders that cause scarring of the organ are pills that circulate...

Apr 30, 2026 • MedCity News

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical ...

Mar 22, 2023 • Yahoo Finance

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical c...

Sep 26, 2023 • Yahoo Finance

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Avalyn), a clinical-stage bio...

May 19, 2024 • Yahoo Finance

Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01

SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical com...

May 22, 2023 • Yahoo Finance